孟鲁司特钠联合阿奇霉素治疗小儿支原体肺炎的效果

Efficacy of Montelukast Sodium Combined with Azithromycin in the Treatment of Mycoplasma Pneumonia in Children

目的:分析孟鲁司特钠联合阿奇霉素治疗支原体肺炎的临床效果。方法:选取2021年5月—2022年5月安顺市西秀区人民医院收治的支原体肺炎患儿80例为研究对象,采用随机数字表法分为参照组和观察组,各40例。参照组采用阿奇霉素治疗,观察组采用孟鲁司特联合阿奇霉素治疗。比较两组治疗总有效率、炎性因子[C反应蛋白(CRP)、降钙素原(PCT)]水平、症状消失时间及不良反应发生率。结果:观察组治疗总有效率高于参照组,差异有统计学意义(P=0.013)。治疗前,两组CRP、PCT水平比较,差异无统计学意义(P>0.05);治疗后,两组CRP、PCT水平低于治疗前,观察组低于参照组,差异有统计学意义(P<0.05)。观察组喘息缓解时间、退热时间、哮鸣音消退时间和咳嗽停止时间短于参照组,差异有统计学意义(P<0.001)。两组不良反应发生率比较,差异无统计学意义(P>0.05)。结论:孟鲁司特钠联合阿奇霉素治疗支原体肺炎的效果较好,可减轻机体炎性反应,改善临床症状,不良反应较少。

Objective:To analyze the clinical effect of Montelukast sodium combined with azithromycin in the treatment of mycoplasma pneumonia.Methods:Eighty children with mycoplasma pneumonia treated in Anshun Xixiu District People's Hospital from May 2021 to May 2022 were selected as the study objects,and were divided into reference group and observation group by random number table method,with forty cases in each group.The reference group was treated with azithromycin,and the observation group was treated with montelukast combined with azithromycin.The total effective rate,the levels of inflammatory factors[C-reactive protein(CRP),procalcitonin(PCT)],the time of symptom resolution and the incidence of adverse reactions were compared between the two groups.Results:The total effective rate of observation group was higher than that of reference group,and the difference was statistically significant(P=0.013).Before treatment,there was no significant difference in CRP and PCT levels between the two groups(P>0.05);after treatment,the levels of CRP and PCT in the two groups were lower than before treatment,and the observation group was lower than the reference group,the difference was statistically significant(P<0.05).The remission time of wheeze,fever,wheeze resolution time and cough cessation time in observation group were shorter than those in reference group,and the difference was statistically significant(P<0.001).There was no significant difference in the incidence of adverse reactions between the two groups(P>0.05).Conclusion:Montelukast sodium combined with azithromycin has a better effect in the treatment of mycoplasma pneumonia,which can reduce inflammatory response,improve clinical symptoms and reduce adverse reactions.